• Explore /
  • Poster
  • / A multicenter phase I study of cabazitaxel (Cbz), mitoxantrone (Mito), and prednisone (Pred) (CAMP) for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC).

A multicenter phase I study of cabazitaxel (Cbz), mitoxantrone (Mito), and prednisone (Pred) (CAMP) for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Rahul Raj Aggarwal

University of California, San Francisco, San Francisco, CA

Rahul Raj Aggarwal , Alan H. Bryce , Vivian K. Weinberg , Charles J. Ryan , Christina Louise Derleth , Andrea Harzstark , Mina Lee , Eric Jay Small

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT01594918

Citation

J Clin Oncol 33, 2015 (suppl 7; abstr 238)

DOI

10.1200/jco.2015.33.7_suppl.238

Abstract #

238

Poster Bd #

C7

Abstract Disclosures

Similar Posters

First Author: Rahul Raj Aggarwal

First Author: Mallika Sachdev Dhawan

First Author: Ethan M. Basch

First Author: Ovidio Fernandez Calvo